Compare GETY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | IFRX |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 303.4M |
| IPO Year | 2022 | 2017 |
| Metric | GETY | IFRX |
|---|---|---|
| Price | $0.41 | $1.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $3.78 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 5.3M | 1.3M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $926,244,000.00 | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $1.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $0.42 | $0.74 |
| 52 Week High | $3.21 | $2.95 |
| Indicator | GETY | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 35.86 |
| Support Level | N/A | $0.87 |
| Resistance Level | $0.93 | $1.94 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 8.00 | 4.26 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.